Investing.com - Roth/MKM initiated coverage on BioAge Labs Inc (NASDAQ:BIOA) with a Buy rating and a price target of $36.00, according to a report released Wednesday.
The firm highlighted the company’s lead asset BGE-102, an oral NLRP3 inhibitor being developed for cardiovascular risk and retinal disease. BGE-102 is the only oral NLRP3 program in development for diabetic macular edema.
The drug candidate produced Phase 1 results showing 86% median hsCRP suppression, with 87% to 93% of patients normalized below 2 mg/L. The company expects Phase 2a cardiovascular data in the second half of 2026.
BioAge Labs has a market capitalization of $738 million, with shares currently trading at $16.20. The stock has delivered exceptional returns of 310% over the past year and 73% in the last six months. The company holds an estimated $385 million in cash, which Roth/MKM projects will fund operations into 2029. According to an InvestingPro tip, the company holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations by a substantial margin.
The company’s platform is based on longitudinal human aging datasets for identifying cardiometabolic targets. BioAge Labs has partnerships with Novartis (NYSE:NVS) and Eli Lilly (NYSE:LLY). Analysts have set price targets ranging from $23 to $73, though InvestingPro analysis suggests the stock may be overvalued at current levels.
In other recent news, BioAge Labs announced results from its Phase 1 clinical trial of the oral NLRP3 inhibitor BGE-102. The trial showed significant reductions in high-sensitivity C-reactive protein, with the 60 mg dose achieving an 85% reduction at day 7 and 86% at day 21, while the 120 mg dose achieved an 83% reduction at day 7 and 86% at day 14. Jefferies reiterated a Buy rating with a $62.00 price target on BioAge Labs, highlighting the potency of BGE-102 and its potential as a best-in-class treatment. The analyst firm noted that the company’s progress has led to an upsized financing, extending its cash runway to 2029. Additionally, Oppenheimer maintained an Outperform rating with a $60.00 price target after BioAge Labs reported its fourth-quarter fiscal 2025 earnings. The company confirmed that the BGE-102 Phase 1 multiple ascending dose readout is on schedule. BioAge Labs has also expanded its Phase 2a study to incorporate dose ranging, with data expected in the second half of the year. These developments underscore the company’s ongoing clinical execution and strategic financial positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for BIOA plus thousands of other stocks and find your next hidden gem with massive upside.